{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:01:25Z","timestamp":1785794485000,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06426-8","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:01:18Z","timestamp":1769536878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metastatic and recurrent salivary gland carcinoma: clinical characteristics and comprehensive molecular profiling at a tertiary care center"],"prefix":"10.1007","volume":"152","author":[{"given":"Tamara","family":"Rordorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Brezina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina A.","family":"Broglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra N.","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Ikenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire B.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels J.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"1","key":"6426_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/COC.0000000000000112","volume":"40","author":"M Airoldi","year":"2017","unstructured":"Airoldi M, Garzaro M, Pedani F et al (2017) Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases. Am J Clin Oncol 40(1):86\u201390","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"6426_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hed.25035","volume":"40","author":"E Boon","year":"2018","unstructured":"Boon E, van Boxtel W, Buter J et al (2018) Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck 40(3):605\u2013613","journal-title":"Head Neck"},{"issue":"11","key":"6426_CR3","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/1055-9965.EPI-09-0638","volume":"18","author":"H Boukheris","year":"2009","unstructured":"Boukheris H, Curtis RE, Land CE, Dores GM (2009) Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 18(11):2899\u20132906","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"6426_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/hed.28124","author":"F Caspani","year":"2025","unstructured":"Caspani F, Cavalieri S, Orlandi E et al (2025) Lenvatinib in relapsed\/metastatic adenoid cystic carcinoma: real-world data from 17 Italian centers. Head Neck. https:\/\/doi.org\/10.1002\/hed.28124","journal-title":"Head Neck"},{"issue":"8","key":"6426_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11864-022-01001-y","volume":"23","author":"LG de Sousa","year":"2022","unstructured":"de Sousa LG, Jovanovic K, Ferrarotto R (2022) Metastatic adenoid cystic carcinoma: genomic landscape and emerging treatments. Curr Treat Options Oncol 23(8):1135\u20131150","journal-title":"Curr Treat Options Oncol"},{"key":"6426_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580141","volume":"10","author":"L Di Villeneuve","year":"2020","unstructured":"Di Villeneuve L, Souza IL, Tolentino FDS et al (2020) Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 10:580141","journal-title":"Front Oncol"},{"issue":"8","key":"6426_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731\u2013739","journal-title":"N Engl J Med"},{"key":"6426_CR8","doi-asserted-by":"crossref","unstructured":"Egebjerg K, Harwood CD, Woller NC et al. (2021) HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis. Front Oncol 11.","DOI":"10.3389\/fonc.2021.693394"},{"issue":"11","key":"6426_CR9","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom LD, Aranda R, Waters L et al (2023) MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov 13(11):2412\u20132431","journal-title":"Cancer Discov"},{"issue":"3","key":"6426_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","volume":"35","author":"R Ferrarotto","year":"2017","unstructured":"Ferrarotto R, Mitani Y, Diao L et al (2017) Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 35(3):352\u2013360","journal-title":"J Clin Oncol"},{"issue":"3","key":"6426_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Mitani Y, McGrail DJ et al (2021) Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res 27(3):852\u2013864","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6426_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.neo.2021.03.008","volume":"23","author":"SN Freiberger","year":"2021","unstructured":"Freiberger SN, Brada M, Fritz C et al (2021) SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 23(5):473\u2013487","journal-title":"Neoplasia"},{"issue":"4","key":"6426_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C, Tada Y, Takahashi H et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29(4):979\u2013984","journal-title":"Ann Oncol"},{"issue":"17","key":"6426_CR14","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.33036","volume":"126","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ, Guenette JP, Chau NG et al (2020) Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer 126(17):3972\u20133981","journal-title":"Cancer"},{"issue":"10","key":"6426_CR15","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","volume":"27","author":"AL Ho","year":"2016","unstructured":"Ho AL, Dunn L, Sherman EJ et al (2016) A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol 27(10):1902\u20131908","journal-title":"Ann Oncol"},{"issue":"5","key":"6426_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70663","volume":"14","author":"CO Hoff","year":"2025","unstructured":"Hoff CO, de Sousa LG, Bonini F et al (2025) Clinical outcomes with notch inhibitors in Notch-Activated recurrent\/metastatic adenoid cystic carcinoma. Cancer Med 14(5):e70663","journal-title":"Cancer Med"},{"issue":"16","key":"6426_CR17","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-24-0455","volume":"30","author":"Y Honma","year":"2024","unstructured":"Honma Y, Monden N, Yamazaki K et al (2024) Apalutamide and goserelin for androgen receptor-positive salivary gland carcinoma: a phase II nonrandomized clinical trial, YATAGARASU. Clin Cancer Res 30(16):3416\u20133427","journal-title":"Clin Cancer Res"},{"key":"6426_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107280","volume":"165","author":"S Kano","year":"2025","unstructured":"Kano S, Kawakita D, Honma Y et al (2025) The impact of HER2-low expression in salivary duct carcinoma: clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy. Oral Oncol 165:107280","journal-title":"Oral Oncol"},{"issue":"1","key":"6426_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00324-1","volume":"6","author":"S Kohsaka","year":"2022","unstructured":"Kohsaka S, Tada Y, Ando M et al (2022) Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. NPJ Precis Oncol 6(1):82","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"6426_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","volume":"25","author":"BT Li","year":"2024","unstructured":"Li BT, Meric-Bernstam F, Bardia A et al (2024) Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 25(6):707\u2013719","journal-title":"Lancet Oncol"},{"key":"6426_CR21","doi-asserted-by":"crossref","unstructured":"Li BT, Shen R, Offin M et al. (2019) Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2019.37.15_suppl.6001"},{"issue":"6","key":"6426_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","volume":"7","author":"L Licitra","year":"1996","unstructured":"Licitra L, Cavina R, Grandi C et al (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7(6):640\u2013642","journal-title":"Ann Oncol"},{"issue":"10","key":"6426_CR23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","volume":"16","author":"VTG Lin","year":"2018","unstructured":"Lin VTG, Nabell LM, Spencer SA et al (2018) First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition. J Natl Compr Canc Netw 16(10):1166\u20131170","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"6426_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.oraloncology.2005.04.014","volume":"41","author":"LD Locati","year":"2005","unstructured":"Locati LD, Guzzo M, Bossi P et al (2005) Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol 41(9):890\u2013894","journal-title":"Oral Oncol"},{"issue":"6","key":"6426_CR25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4161\/cbt.28410","volume":"15","author":"LD Locati","year":"2014","unstructured":"Locati LD, Perrone F, Cortelazzi B et al (2014) Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther 15(6):678\u2013682","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"6426_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hed.23940","volume":"38","author":"LD Locati","year":"2016","unstructured":"Locati LD, Perrone F, Cortelazzi B et al (2016) Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers. Head Neck 38(5):724\u2013731","journal-title":"Head Neck"},{"issue":"10","key":"6426_CR27","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/hed.25891","volume":"41","author":"LD Locati","year":"2019","unstructured":"Locati LD, Cavalieri S, Bergamini C et al (2019) Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck 41(10):3670\u20133676","journal-title":"Head Neck"},{"issue":"9","key":"6426_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/cncr.32754","volume":"126","author":"LD Locati","year":"2020","unstructured":"Locati LD, Galbiati D, Calareso G et al (2020) Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer 126(9):1888\u20131894","journal-title":"Cancer"},{"issue":"1","key":"6426_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42(1):47\u201358","journal-title":"J Clin Oncol"},{"issue":"13","key":"6426_CR30","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1245\/s10434-016-5356-3","volume":"23","author":"SJ Nam","year":"2016","unstructured":"Nam SJ, Roh JL, Cho KJ et al (2016) Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 23(13):4376\u20134383","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6426_CR31","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","volume":"42","author":"A Skalova","year":"2018","unstructured":"Skalova A, Stenman G, Simpson RHW et al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):e11\u2013e27","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"6426_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12105-022-01420-1","volume":"16","author":"A Sk\u00e1lov\u00e1","year":"2022","unstructured":"Sk\u00e1lov\u00e1 A, Hyrcza MD, Leivo I (2022) Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. Head Neck Pathol 16(1):40\u201353","journal-title":"Head Neck Pathol"},{"issue":"10","key":"6426_CR33","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B et al (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 23(10):1261\u20131273","journal-title":"Lancet Oncol"},{"key":"6426_CR34","doi-asserted-by":"crossref","unstructured":"Swed BL, Cohen RB, Aggarwal C (2019) Targeting HER2\/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience. JCO Precis Oncol 3.","DOI":"10.1200\/PO.18.00351"},{"issue":"2","key":"6426_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37(2):125\u2013134","journal-title":"J Clin Oncol"},{"issue":"4","key":"6426_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jjco\/hyad181","volume":"54","author":"S Takahashi","year":"2024","unstructured":"Takahashi S, Bando H, Kinoshita I et al (2024) Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Jpn J Clin Oncol 54(4):434\u2013443","journal-title":"Jpn J Clin Oncol"},{"issue":"18","key":"6426_CR37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian V, Sherman EJ, Dunn L et al (2019) Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 37(18):1529\u20131537","journal-title":"J Clin Oncol"},{"issue":"22","key":"6426_CR38","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ et al (2023) Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 388(22):2058\u20132070","journal-title":"N Engl J Med"},{"issue":"3","key":"6426_CR39","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMc2415114","volume":"392","author":"NC Turner","year":"2025","unstructured":"Turner NC, Thanopoulou E, Jhaveri KL (2025) Inavolisib therapy in advanced breast cancer. Reply. N Engl J Med 392(3):310\u2013311","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06426-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06426-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:01:19Z","timestamp":1769536879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06426-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6426"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06426-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"46"}}